Baicheng Pharmaceutical announced that Baicheng Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received a clinical trial approval notice from the State Drug Administration. The self-developed HQ2303 drug will carry out clinical trial research. The HQ2303 registration classification is category 2, and the indication is to treat essential hypertension.

Zhitongcaijing · 6d ago
Baicheng Pharmaceutical announced that Baicheng Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received a clinical trial approval notice from the State Drug Administration. The self-developed HQ2303 drug will carry out clinical trial research. The HQ2303 registration classification is category 2, and the indication is to treat essential hypertension.